-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Sunday, Allogene Reports 31% Confirmed Response Rate With ALLO-316 In CD70-High RCC Patients At ASCO, With Durable Remissions And Manageable Safety

Benzinga·06/02/2025 06:57:54
Listen to the news
  • Data Highlights Transformative Promise of CAR T in Solid Tumors
  • Phase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC
    • A Single Dose of ALLO-316 Achieved a 31% Confirmed Response Rate
    • Four of Five Confirmed Responders Remain in Response Including One Ongoing Remission Over 12 Months
  • Robust Expansion, Persistence, and Tumor Infiltration of ALLO-316 Seen with Standard Lymphodepletion, Showcasing Dagger® Technology as a Next-Generation Allogeneic Platform
  • Phase 1 Safety Profile was Manageable; Proactive Diagnostic and Management Strategies Proved Effective in Mitigating IEC-HS While Preserving Efficacy